[1]
|
Du, L. and Ha, C. (2020) Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterology Clinics of North America, 49, 643-654. https://doi.org/10.1016/j.gtc.2020.07.005
|
[2]
|
Ungaro, R., Mehandru, S., Allen, P.B., Pey-rin-Biroulet, L. and Colombel, J.-F. (2017) Ulcerative Colitis. The Lancet, 389, 1756-1770. https://doi.org/10.1016/S0140-6736(16)32126-2
|
[3]
|
Roda, G., Jharap, B., Neeraj, N. and Colombel, J.-F. (2016) Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clinical and Translational Gastroenter-ology, 7, e135. https://doi.org/10.1038/ctg.2015.63
|
[4]
|
Hirten, R.P. and Sands, B.E. (2021) New Therapeutics for Ulcerative Colitis. Annual Review of Medicine, 72, 199-213.
https://doi.org/10.1146/annurev-med-052919-120048
|
[5]
|
Battat, R., Dulai, P.S., Jairath, V. and Vande Casteele, N. (2019) A Product Review of Vedolizumab in Inflammatory Bowel Disease. Human Vaccines & Immunotherapeutics, 15, 2482-2490.
https://doi.org/10.1080/21645515.2019.1591139
|
[6]
|
Zundler, S., Becker, E., Schulze, L.L. and Neurath, M.F. (2019) Immune Cell Trafficking and Retention in Inflammatory Bowel Disease: Mechanistic in Sights and Therapeutic Advances. Gut, 68, 1688-1700.
https://doi.org/10.1136/gutjnl-2018-317977
|
[7]
|
Ley, K., Rivera-Nieves, J., Sandborn, W.J. and Shattil, S. (2016) Integrin-Based Therapeutics: Biological Basis, Clinical Use and New Drugs. Nature Reviews Drug Discovery, 15, 173-183. https://doi.org/10.1038/nrd.2015.10
|
[8]
|
Takada, Y., Ye, X., and Simon, S. (2007) The Integrins. Ge-nome Biology, 8, Article No. 215.
https://doi.org/10.1186/gb-2007-8-5-215
|
[9]
|
Wyant, T., Fedyk, E. and Abhyankar, B. (2016) An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. Journal of Crohn’s and Colitis, 10, 1437-1444. https://doi.org/10.1093/ecco-jcc/jjw092
|
[10]
|
Li, H., Huang, S.-Y., Shi, F.-H., Gu, Z.-C., Zhang, S.-G. and Wei, J.-F. (2018) α4β7 Integrin Inhibitors: A Patent Review. Expert Opinion on Therapeutic Patents, 28, 903-917. https://doi.org/10.1080/13543776.2018.1549227
|
[11]
|
Feagan, B.G., Rutgeerts, P., Sands, B.E., Hanauer, S., Co-lombel, J.F., Sandborn, W.J., et al. (2013) Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 369, 699-710.
https://doi.org/10.1056/NEJMoa1215734
|
[12]
|
Motoya, S., Watanabe, K., Ogata, H., Kanai, T., Matsui, T., Suzuki, Y., et al. (2019) Vedolizumab in Japanese Patients with Ulcerative Colitis: A Phase 3, Randomized, Double-Blind, Pla-cebo-Controlled Study. PLOS ONE, 14, e0212989.
https://doi.org/10.1371/journal.pone.0212989
|
[13]
|
Loftus Jr., E.V., Colombel, J.F., Feagan, B.G., Vermeire, S., Sandborn, W.J., Sands, B.E., et al. (2017) Long-Term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn’s and Colitis, 11, 400-411.
https://doi.org/10.1093/ecco-jcc/jjw177
|
[14]
|
Feagan, B.G., Rubin, D.T., Danese, S., Vermeire, S., Abhyankar, B., Sankoh, S., et al. (2017) Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients with Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology, 15, 229-239.
https://doi.org/10.1016/j.cgh.2016.08.044
|
[15]
|
Sands, B.E., Peyrin-Biroulet, L., Loftus Jr., E.V., Danese, S., Co-lombel, J.F., Törüner, M., et al. (2019) Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 381, 1215-1226.
https://doi.org/10.1056/NEJMoa1905725
|
[16]
|
Arijs, I., De Hertogh, G., Lemmens, B., Van Lommel, L., de Bruyn, M., Vanhove, W., et al. (2018) Effect of Vedolizumab (Anti-α4β7-Integrin) Therapy on Histological Healing and Muco-sal Gene Expression in Patients with UC. Gut, 67, 43-52. https://doi.org/10.1136/gutjnl-2016-312293
|
[17]
|
Narula, N., Peerani, F., Meserve, J., Kochhar, G., Chaudrey, K., Hartke, J., et al. (2018) Open: Vedolizumab for Ulcerative Coli-tis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 113, 1345.
https://doi.org/10.1038/s41395-018-0162-0
|
[18]
|
Baumgart, D.C., Bokemeyer, B., Drabik, A., Stallmach, A., Schreiber, S. and the Vedolizumab Germany Consortium (2016) Vedolizumab Induction Therapy for Inflammatory Bowel Disease in Clinical Practice—A Nationwide Consecutive German Cohort Study. Alimentary Pharmacology & Therapeutics, 43, 1090-1102.
https://doi.org/10.1111/apt.13594
|
[19]
|
Plevris, N., Chuah, C.S., Allen, R.M., Arnott, I.D., Brennan, P.N., et al. (2019) Real-World Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Journal of Crohn’s and Colitis, 13, 1111-1120. https://doi.org/10.1093/ecco-jcc/jjz042
|
[20]
|
Bressler, B., Yarur, A., Silverberg, M.S., Bassel, M., Bellaguarda, E., Fourment, C., et al. (2021) Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. Journal of Crohn’s and Colitis, 15, 1694-1706.
https://doi.org/10.1093/ecco-jcc/jjab058
|
[21]
|
Garcia-Romero, R., Martinez de Zabarte Fernandez, J.M., Pu-jol-Muncunill, G., Donat-Aliaga, E., Segarra-Cantón, O., Irastorza-Terradillos, I., et al. (2021) Safety and Effectiveness of Vedolizumab in Paediatric Patients with Inflammatory Bowel Disease: An Observational Multicentre Spanish Study. European Journal of Pediatrics, 180, 3029-3038.
https://doi.org/10.1007/s00431-021-04063-6
|
[22]
|
Schneider, AM., Weghuber, D., Hetzer, B., Entenmann, A., Müller, T., Zimmermann, G., et al. Vedolizumab Use after Failure of TNF-α Antagonists in Children and Adolescents with Inflammatory Bowel Disease. BMC Gastroenterology, 18, Article No. 140. https://doi.org/10.1186/s12876-018-0868-x
|
[23]
|
Shashi, P., Gopalakrishnan, D., Parikh, M.P., Shen, B. and Kochhar, G. (2020) Efficacy and Safety of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Matched Case-Control Study. Gastroenterology Report, 8, 306-311.
https://doi.org/10.1093/gastro/goz041
|
[24]
|
Moens, A., van der Woude, C.J., Julsgaard, M., Humblet, E., Sheridan, J., Baumgart, D.C., et al. (2020) Pregnancy Outcomes in Inflammatory Bowel Disease Patients Treated with Vedoli-zumab, Anti-TNF or Conventional Therapy: Results of the European CONCEIVE Study. Alimentary Pharmacology & Therapeutics, 51, 129-138.
https://doi.org/10.1111/apt.15539
|
[25]
|
Loftus Jr., E.V., Feagan, B.G., Panaccione, R., Colombel, J.F., Sandborn, W.J., Sands, B.E., et al. (2020) Long-Term Safety of Vedolizumab for Inflammatory Bowel Disease. Alimentary Phar-macology & Therapeutics, 52, 1353-1365.
https://doi.org/10.1111/apt.16060
|
[26]
|
Cohen, R.D., Bhayat, F., Blake, A. and Travis, S. (2020) The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-Marketing Data. Journal of Crohn’s and Colitis, 14, 192-204.
https://doi.org/10.1093/ecco-jcc/jjz137
|
[27]
|
Ng, S.C., Hilmi, I.N., Blake, A., Bhayat, F., Adsul, S., Khan, Q.R., et al. (2018) Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases, 24, 2431-2441. https://doi.org/10.1093/ibd/izy153
|